All In Biotech

Drug Trial Radar · NCT06087458

Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1/2a Study of VOY-101 in Subjects With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 21, 2023

Primary completion

Oct 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Perceive Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.

Conditions

  • Age-Related Macular Degeneration
  • Geographic Atrophy
  • Non-neovascular AMD
  • Non-neovascular Age-related Macular Degeneration

Interventions

  • VOY-101Biological

    VOY-101

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101Time frame: 24 Months
  2. Phase 1: Change from Baseline in markers of inflammationTime frame: Baseline to Month 24
  3. Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.Time frame: Month 12
  4. Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.Time frame: 15 Months

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Retina Macula Institute of AZ

    Scottsdale, Arizona

  • Retina Consultants San Diego

    Poway, California

  • Retinal Consultants Medical Group

    Sacramento, California

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • The Retina Institute

    St Louis, Missouri

  • Mid Atlantic Retina

    Cherry Hill, New Jersey

  • Retina Northwest

    Portland, Oregon

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota

  • Austin Research Center for Retina

    Austin, Texas

  • Star Retina

    Fort Worth, Texas

  • Retina Center of Texas

    Southlake, Texas

  • University of Utah John A. Moran Eye Center

    Salt Lake City, Utah

  • Sydney Retina Clinic and Day Surgery

    Sydney, New South Wales, Australia

  • Cerulea Clinical Trials

    East Melbourne, Victoria, Australia

  • Rambam Medical Center

    Haifa, Israel

  • Tel-Aviv Sourasky Medical Center, Ophthalmology Division

    Tel Aviv, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.